Skip to main content

Table 5 Results of one-way and two-way sensitivity analyses

From: Introduction of birth dose of hepatitis B virus vaccine to the immunization program in Ethiopia: an economic evaluation

One-way Two-way
Parameters Range for sensitivity analysis ICER (US$ per DALY averted) Parameters with range for sensitivity analysis ICER (US$ per DALY averted)
Vaccine effectiveness 80% 93 Vaccine effectiveness (60–80%) + Vaccine utilization (10–66%) 88
60% 169 663
Vaccine utilization 66% 90 Vaccine effectiveness (60–80%) + Risk of perinatal transmission (HBeAg −) (2%–29%) CS
10% 625 475
Risk of perinatal transmission (HBeAg −) 29% CS Vaccine effectiveness (60–80%) + Prevalence of HBV infection among mothers (2.5–10%) (10–66%) CS
2% 373 421
Prevalence of HBV infection among mothers 10% CS Vaccine effectiveness (60%–80%) + Cost of medical care (from no cost to twice the cost of morbid states) (10–66%) CS
2.5% 328 207
Cost of medical care Twice the cost CS Vaccine effectiveness (60–80%) + Average cost per vaccinated child ($0.5–1.0) (10–66%) 13
No cost 158 262
Average cost per vaccinated child $0.5 29 Vaccine effectiveness (60–80%) + Risk of perinatal transmission (HBeAg +) (14–56%) 32
$1.0 195 214
Risk of prinatal transmission (HBeAg +) 56% 51 Vaccine effectiveness (60–80%) + Prevalence of HBeAg in pregnant women (5–25%) (10–66%) 40
14% 156 202
Prevalence of HBeAg in pregnant women 25% 59 Vaccine effectiveness (60–80%) + Transition prob. of CAH to inactive carrier state (30–70%) (10–66%) 35
5% 146 174
Transition prob. of CAH to inactive carrier state 30% 60   
70% 124   
  1. CS cost saving